ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

4:00PM-5:30PM: Abstract Number: 2527

Risk Factors for Bone Loss in Systemic Lupus Erythematosus

Abstracts: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science

4:00PM-5:30PM: Abstract Number: 2560

Risk of Gastrointestinal Perforation Among Patients with Giant Cell Arteritis Who Received Tocilizumab

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2506

Role of TGF-β Activated Kinase 1 in Cytokine-Driven Juvenile Idiopathic Arthritis Synovial Fibroblasts Activation

Abstracts: Cytokines & Cell Trafficking

4:00PM-5:30PM: Abstract Number: 2538

Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

4:00PM-5:30PM: Abstract Number: 2526

Single-cell RNA Sequencing Reveals the CRTAC1+ Population Actively Contributes to the Pathogenesis of Spinal Ligament Degeneration by Inducing Macrophage Activation

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

4:00PM-5:30PM: Abstract Number: 2535

Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management

Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

4:00PM-5:30PM: Abstract Number: 2511

Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies

Abstracts: Immunological Complications of Medical Therapy

4:00PM-5:30PM: Abstract Number: 2512

Targeted Therapies for Severe Immune-related Adverse Events of Immune Checkpoint Inhibitors Are Not Associated with a Worse Prognosis

Abstracts: Immunological Complications of Medical Therapy

4:00PM-5:30PM: Abstract Number: 2504

The Effect of Inflammatory Conditions on the Regulation of Canonical and Non-canonical NF-kB Pathways via Bcl11b

Abstracts: Cytokines & Cell Trafficking

4:00PM-5:30PM: Abstract Number: 2516

The Effect of Starting Prednisone Dose on the Treatment of Polymyalgia Rheumatica

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2550

The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment III: AxSpA

4:00PM-5:30PM: Abstract Number: 2540

The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response

Abstracts: RA – Treatments III: Predictors of Response & Tapering

4:00PM-5:30PM: Abstract Number: 2561

The Prognostic Value of the “2022 ACR/EULAR Classification Criteria for Giant Cell Arteritis”: Data from the Italian Society of Rheumatology Vasculitis Study Group

Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II: Clinical

4:00PM-5:30PM: Abstract Number: 2517

The Relationship Between the NETosis Findings and Disease Activity in Behcet Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II

4:00PM-5:30PM: Abstract Number: 2521

Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].